Lv1
80 积分 2021-06-04 加入
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
6天前
已完结
Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment
11天前
已完结
PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer
13天前
已完结
Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer
22天前
已完结
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
25天前
已完结
Gastric cancer
26天前
已完结
The evolving immuno-angiogenic paradigm in NSCLC: lessons from ivonescimab
28天前
已完结
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
29天前
已完结
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
1个月前
已完结
Chemistry, manufacturing and controls strategies for using novel excipients in lipid nanoparticles
1个月前
已完结
皖公网安备34019202002308
